US2020253865A1PendingUtilityA1

Supraparticles

64
Assignee: THE BIONICS INST OF AUSTRALIAPriority: Sep 20, 2017Filed: Sep 20, 2018Published: Aug 13, 2020
Est. expirySep 20, 2037(~11.2 yrs left)· nominal 20-yr term from priority
Inventors:Andrew WiseFrank CarusoMattias BjornmalmYutian Ma
A61K 9/5161A61K 9/5192A61K 9/06A61K 9/5115A61K 47/36B82Y 5/00A61K 9/1611A61P 27/16A61K 9/5052A61K 9/1652A61K 38/185A61K 9/0046A61K 38/2073A61K 9/167A61K 31/573A61K 9/1635A61K 9/146A61K 9/0024A61K 38/18A61K 2300/00A61K 47/6923
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure relates to improved supraparticles loaded with high levels of payload and methods for their production. Such supraparticles may be used in a range of therapeutic applications, for example, to improve growth or survival of cells and/or treat disease.

Claims

exact text as granted — not AI-modified
1 . A composition comprising a supraparticle, wherein the supraparticle comprises at least 1.5 μg of payload. 
     
     
         2 . The composition of  claim 1 , wherein the supraparticle comprises at least 5 μg of payload. 
     
     
         3 . The composition of  claim 1 , wherein the supraparticle comprises 1.5 μg to 10 μg of payload. 
     
     
         4 . The composition according to any one of  claims 1  to  3 , wherein the supraparticle comprises pores having a diameter of at least 60 nm. 
     
     
         5 . The composition according to any one of  claims 1  to  3 , wherein the supraparticle comprises pores having a diameter of at least 50-100 nm. 
     
     
         6 . The composition according to any one of  claims 1  to  5 , wherein the supraparticles have a disordered pore structure. 
     
     
         7 . The composition according to any one of  claims 1  to  6 , wherein the supraparticle is comprised of nanoparticles having a bimodal pore structure. 
     
     
         8 . The composition of  claim 7 , wherein the nanoparticles bimodal pore structure has a large pore diameter greater than 30 nm. 
     
     
         9 . The composition according to any one of  claims 1  to  8 , wherein the payload is a small molecule, a peptide or a protein. 
     
     
         10 . The composition according to anyone of  claims 1  to  10 , wherein the payload is a stem cell, virus, nucleic acid, neurotrophic factor, anti-cancer agent, neuroprotectant or combination thereof. 
     
     
         11 . The composition according to any one of  claims 1  to  9 , wherein the payload is a neurotrophic factor. 
     
     
         12 . The composition according to  claim 11 , wherein the neurotrophic factor has an isoelectric point between 9 and 10. 
     
     
         13 . The composition according to any one of  claims 1  to  10 , wherein the neurotrophic factor is BDNF. 
     
     
         14 . The composition according to any one of  claims 1  to  10 , wherein the neurotrophic factor is neurotrophin-3. 
     
     
         15 . The composition according to any one of  claims 1  to  14 , wherein the supraparticle comprises at least 2, at least 3, at least 4, at least 5 different payloads. 
     
     
         16 . The composition of  claim 15 , wherein the supraparticle comprises at least two payloads, one payload being a neurotrophic factor. 
     
     
         17 . The composition according to any one of  claims 1  to  15 , which comprises at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least 10 supraparticles. 
     
     
         18 . The composition according to  claim 17 , which comprises supraparticles with different payloads. 
     
     
         19 . The composition according to any one of  claims 1  to  18 , wherein the composition is provided as a slow release formulation. 
     
     
         20 . The composition of  claim 19 , which comprises a glycogen hydrogel. 
     
     
         21 . The composition according to any one of  claims 1  to  20 , wherein the supraparticles are manufactured by electrospraying a composition comprising nanoparticles and alginic acid or a polysaccharide derivative thereof into a di-cationic aqueous solution. 
     
     
         22 . The composition according to any one of  claims 1  to  21 , comprising Alginic acid [(C 6 H 8 O 6 ) n ] or a polysaccharide derivative thereof. 
     
     
         23 . The composition according to  claim 22 , which comprises Alginic acid sodium salt [Na(C 6 H 8 O 6 ) n ] or a polysaccharide derivative thereof. 
     
     
         24 . Use of a composition according to any one of  claims 1  to  24  in the manufacture of a medicament for treating a disease or disorder. 
     
     
         25 . The use of  claim 25 , wherein the disorder is hearing loss. 
     
     
         26 . The use of  claim 26 , wherein the hearing loss is characterised as sensorineural hearing loss (SNHL), presbycusis or noise induced. 
     
     
         27 . A method for promoting survival of spiral ganglion neurons in an ear of a subject, the method comprising administering the composition of any one of  claims 1  to  23  to a subject. 
     
     
         28 . A method for treating a condition in which sustained delivery of a therapeutic payload is desirable in a subject, the method comprising administering the composition of any one of  claims 1  to  23  to a subject. 
     
     
         29 . The method of  claim 27  or  claim 28 , wherein the composition is administered to an ear of a subject. 
     
     
         30 . The method of  claim 27  or  claim 28 , wherein the composition is administered intraperitoneally. 
     
     
         31 . The method of  claim 27  or  claim 28 , wherein the composition is administered in a scaffold which retains the supraparticles. 
     
     
         32 . A kit comprising a composition according to any one of  claims 1  to  23  when 30 used for treating a disease or disorder. 
     
     
         33 . The kit of  claim 32 , wherein the disorder is hearing loss. 
     
     
         34 . The kit of  claim 33 , further comprising a cochlear implant. 
     
     
         35 . A composition comprising nanoparticles and Alginic acid when used for manufacturing supraparticles. 
     
     
         36 . The composition of  claim 35 , wherein the Alginic acid is Alginic acid sodium salt. 
     
     
         37 . Method of manufacturing supraparticles comprising electrospraying a composition comprising nanoparticles and alginic acid or a polysaccharide derivative thereof into a di-cationic aqueous solution. 
     
     
         38 . The method of  claim 37 , further comprising subjecting the supraparticles to calcination to remove alginic acid. 
     
     
         39 . The method of  claim 38 , wherein calcination is performed at around 650° C. 
     
     
         40 . The method of  claim 38 , wherein the calcination is performed for about 6 to about 30 hours.

Join the waitlist — get patent alerts

Track US2020253865A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.